Autoimmune Disease of the Joints in Dogs (Erosive, Immune-Mediated Polyarthritis)
- Occurrence: very rare
- Location of disease: Legs
When to visit the vet?
Urgent see a veterinarian within 24 hours
If the condition worsens / symptoms persist, consult a veterinarian.
Definition
Erosive, immune-mediated polyarthritis in dogs is an inflammatory joint disease caused by the dog’s immune system and leads to damage to the articular cartilage.
The most important facts at a glance
Erosive, immune-mediated polyarthritis in dogs is an autoimmune disease in which the immune system attacks the joints and leads to destruction of the articular cartilage. This disease develops when the immune system can no longer distinguish the body’s own cells from foreign ones; genetic factors, environmental conditions and infections can play a role. Symptoms include Lameness, a stiff gait, Reluctance to move, and Joint pain. Diagnosis is made through a clinical examination, imaging such as X-ray and MRI, and laboratory tests. Treatment aims to reduce Inflammatory conditions and modulate the immune system, using anti-inflammatory medications and immunosuppression. Physiotherapy and supplements can provide support. The prognosis depends on the severity of the disease and the response to therapy. Early diagnosis and consistent treatment are crucial for a good quality of life. Prevention is difficult, but a balanced diet and regular exercise can reduce the risk. Research focuses on immunological mechanisms, genetic predisposition, and new therapies such as monoclonal antibodies. Non-invasive diagnostic techniques are also being developed to improve early detection.
Causes
Erosive, immune-mediated polyarthritis is one of the autoimmune diseases in which the immune system mistakenly attacks the body’s own structures. In this specific form of arthritis, the joints are affected; the inflammation leads to destruction of the articular cartilage. Cartilage is an important tissue that covers the ends of bones in a joint and serves as a cushion and a smooth gliding surface.
Immune-mediated diseases develop when the immune system can no longer distinguish between the body’s own cells and foreign cells. Genetic factors, environmental conditions and infections can contribute to dysregulation of the immune system. In dogs with erosive polyarthritis, misdirected immune cells attack joint structures, leading to inflammation and ultimately erosion of the cartilage.
Causes of the disease include genetic predispositions, which may be more common in certain dog breeds. Infections and environmental factors such as stress or chemical exposure can also act as triggers. However, the exact cause of the disease is often multifactorial and not always clearly identifiable.
Symptoms
The symptoms of erosive, immune-mediated polyarthritis are varied and can vary in severity. The most common symptoms are lameness, swelling, and pain in the affected joints. Affected dogs often show reduced mobility and avoid activities that cause them pain.
In addition to lameness, there may be stiffness of the joints, especially after periods of rest or in the morning. Dogs with this condition may also show general symptoms such as fever, lethargy, and loss of appetite. In advanced stages, the inflammation can lead to permanent joint damage, which significantly impairs the dog’s quality of life.
Therapy
Treatment of erosive, immune-mediated polyarthritis aims to reduce inflammation, relieve Pain, and modulate the immune system. A key pillar of therapy is anti-inflammatory medication such as NSAID (non-steroidal anti-inflammatory drug), which helps relieve Pain and Inflammatory conditions.
Immunosuppression can also be used to dampen the overactive immune response. These medications are important to prevent progression of joint damage. In some cases, the veterinarian may also prescribe corticosteroids to treat acute flare-ups of the disease.
In addition to drug therapy, physiotherapy can be helpful to maintain joint mobility and prevent muscle atrophy. A balanced diet and supplements containing omega-3 fatty acids and glucosamine can also provide support.
Prognosis and follow-up care
The prognosis for dogs with erosive, immune-mediated polyarthritis depends on the severity of the disease and the response to treatment. With early diagnosis and consistent therapy, many dogs can maintain a good quality of life and the progression of the disease can be slowed.
However, the disease can be chronic and often requires lifelong treatment and monitoring. Without appropriate therapy, severe joint damage can occur, significantly limiting the dog’s mobility and reducing its quality of life.
Prevention
Because the exact cause of erosive, immune-mediated polyarthritis is often multifactorial, there is no specific prevention measure that can completely prevent the disease. However, some general measures can reduce the risk of developing it.
A balanced diet and a healthy weight can help promote joint health and avoid overstressing them. Regular exercise is also important to maintain joint function, but should be adapted to the needs of the dog to avoid overexertion.
Regular veterinary check-ups are crucial to detect early signs of joint disease and take action if needed. In dogs with a genetic predisposition to autoimmune disease, close monitoring and early intervention can be beneficial.
Outlook on current research
Research into erosive, immune-mediated polyarthritis in dogs is currently focused on understanding the exact immunological mechanisms that lead to this disease. A particular focus is on the role of different immune cells and the cytokines they produce—signaling molecules that regulate Inflammatory conditions in the body. Researchers are trying to determine which specific cell types and signaling pathways in the joints of affected dogs are overactive and lead to the cartilage destruction observed. These insights could help develop targeted therapeutics that act specifically on these pathways and thus stop inflammation and progressive cartilage damage.
Another exciting area of research is the genetic predisposition to this type of arthritis in dogs. Scientists are investigating which genetic markers or mutations are associated with an increased risk of developing the disease. By identifying genetic factors, researchers hope to support breeding programs that can reduce the risk of this disease. In addition, genetic tests could be developed to identify at-risk dogs early.
Current studies are also exploring the use of newer biological therapies such as monoclonal antibodies that block specific inflammatory mediators. These therapies could enable more precise treatment by modulating the immune response without suppressing the entire immune system. Early clinical studies have already shown promising results, with affected dogs showing a marked reduction in inflammatory symptoms and an improvement in quality of life.
Research is also looking at the role of diet and supplements in supporting joint health and reducing inflammation. Omega-3 fatty acids, glucosamine and chondroitin are some of the supplements being studied to assess their potentially beneficial effects on joint health in dogs with immune-mediated polyarthritis.
Another aspect of research focuses on developing non-invasive diagnostic techniques to detect the disease early and monitor its progression. Imaging methods such as magnetic resonance imaging (MRI) and advanced ultrasound techniques are being tested to improve accuracy and reliability in assessing joint damage. In the future, these technologies could enable earlier diagnosis and individually tailored therapy planning.
Frequently Asked Questions (FAQs)
1. What is erosive, immune-mediated polyarthritis in dogs?
2. What symptoms do dogs with this disease show?
3. How is this disease diagnosed?
4. What Treatment Options are Available?
5. Can diet help with treatment?
6. Can this disease be cured?
7. Which dog breeds are most commonly affected?
8. How can I help my dog with this disease?
9. How often should a dog with this disease be examined by the veterinarian?
10. Are there new treatment approaches in development?
Literature
- Shaughnessy, M. L., Sample, S. J., Abicht, C., Heaton, C., & Muir, P. (2016). Clinical features and pathological joint changes in dogs with erosive immune-mediated polyarthritis: 13 cases (2004–2012). Journal of the American Veterinary Medical Association, 249(10), 1156–1164. https://doi.org/10.2460/javma.249.10.1156
- Bennett, D. (1987). Immune-based erosive inflammatory joint disease of the dog: Canine rheumatoid arthritis. 1. Clinical, radiological and laboratory investigations. Journal of Small Animal Practice, 28, 779–797. https://doi.org/10.1111/j.1748-5827.1987.tb01345.x
- Bennett, D. (1987). Immune-based erosive inflammatory joint disease of the dog: Canine rheumatoid arthritis. 2. Pathological investigations. Journal of Small Animal Practice, 28, 799–819. https://doi.org/10.1111/j.1748-5827.1987.tb01346.x
- Pedersen, N. C., Pool, R. R., Castles, J. J., & Weisner, K. (1976). Noninfectious canine arthritis: Rheumatoid arthritis. Journal of the American Veterinary Medical Association, 169(3), 295–303.
- Carter, S. D., Bell, S. C., Bari, A. S. M., & Bennett, D. (1989). Immune complexes and rheumatoid factors in canine arthritides. Annals of the Rheumatic Diseases, 48(12), 986–991. https://doi.org/10.1136/ard.48.12.986
- Johnson, K. C., & Mackin, A. (2012). Canine immune-mediated polyarthritis: Part 1: Pathophysiology. Journal of the American Animal Hospital Association, 48(1), 12–17. https://doi.org/10.5326/JAAHA-MS-5744
- Johnson, K. C., & Mackin, A. (2012). Canine immune-mediated polyarthritis: Part 2: Diagnosis and treatment. Journal of the American Animal Hospital Association, 48(2), 71–82. https://doi.org/10.5326/JAAHA-MS-5756
- Ravicini, S., Kent, A., Dunning, M., Baines, S., Clarke, S., & Allerton, F. (2023). Description and outcome of dogs with primary immune-mediated polyarthritis: 73 cases (2012–2017). Journal of Small Animal Practice, 64, 142–148. https://doi.org/10.1111/jsap.13565
- Cruzado Perez, J., Travail, V., Lamb, V., & Kelly, D. (2024). Canine immune-mediated polyarthritis: A review of 84 cases in the UK between 2011 and 2021. Veterinary Medicine and Science, 10, Article e1306. https://doi.org/10.1002/vms3.1306
- Wilson, R., Swift, I., Groth-Semple, M., Lee, S., Dann, T., Arafa, A., Poyton, C., & Thompson, M. (2024). Treatment with leflunomide in conjunction with glucocorticoids for dogs with immune-mediated polyarthritis is not associated with improved outcomes: A retrospective cohort study of 93 dogs from Australia (2017–2024). Veterinary Sciences, 11(11), Article 537. https://doi.org/10.3390/vetsci11110537